## **Supporting information**



**SI Figure 1.** <sup>15</sup>N NMR spectra of (A) N-Succinimidyl 1,3-(2-pyridyldithio) propionate (SPDP) and (B) liposome-SPDP conjugate.





**SI Figure 2.** <sup>1</sup>H NMR spectra of (A) liposome- N-Succinimidyl 1,3-(2-pyridyldithio) propionate (SPDP), (B) CAR-conjugated liposome, and (C) 2D-correlation spectroscopy (COSY) NMR of liposome-SPDP.



В	Acquisition Time (sec)	4.0894	Date	16 Feb 2019 18:46:56			Date Stamp	16 Feb 2019 18:46:56	
	File Name	\lalbany.ttuhsc.edu\PharmaceuticalSciAma_NMRUsers\Aho\AK-1(Fas-Lipo)\11\fid					Frequency (MHz)	400.13	
	Nucleus	1H	Number of Transients	120	Origin	spect	Original Points Count	32768	
	Owner	nmrsu	Points Count	32768	Pulse Sequence	zg30	Receiver Gain	181.00	
	SW(cyclical) (Hz)	8012.82	Solvent	DMSO-d6	Spectrum Offset (Hz)	2470.8027	Spectrum Type	STANDARD	
	Sween Width (Hz)	8012 58	Temperature (degree C)	22.818					



SI Figure 3. <sup>1</sup>H NMR spectra of plain fasudil (A) and CAR-conjugated liposome containing fasudil (B).

4



**SI Figure 4.** The percentage of fasudil, calculated, remained in the lungs and IPRL circuitry after perfusing the lungs with plain fasudil and various liposomal formulations of fasudil given via the intravenous-mimicking route (cannulated pulmonary artery) into (A and C) sham and (B and D) PAH lungs. The percentage remained was calculated by subtracting the amount of drug in the perfusate from the total amount added to the perfusion medium.



**SI Figure 5.** The percentage of fasudil, calculated, remained in the lungs and perfusate circuitry after perfusing the lungs with plain fasudil and various liposomal formulations of fasudil given via the inhalation-mimicking route (intratracheal instillation) into (A and C) sham and (B and D) PAH lungs. The percentage of drug remained was calculated by subtracting the amount of drug in the perfusate from the total amount added to the perfusion medium.